291 results on '"Shepherd, F.A."'
Search Results
52. 2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
53. 2192P Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
54. LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
55. 1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
56. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: A case study of NCIC CTG BR21
57. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
58. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience
59. Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment
60. 356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
61. 85 Long-term outcome after en bloc resection of non–small cell lung cancer invading the pulmonary sulcus and spine.
62. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer
63. LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
64. A Randomized Trial of the Electronic Lung Cancer Symptom Scale for Quality-of-Life Assessment in Patients with Advanced Non-small-Cell Lung Cancer
65. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
66. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience
67. Somatic alteration burden involving non-cancer genes predicts prognosis in early-stage non-small cell lung cancer
68. Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study
69. Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort
70. 81P The influence of comorbidity on health utility score (HUS) and health-related quality of life (HRQoL) in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC)
71. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
72. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
73. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors
74. 475O - Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
75. Outcomes for Cervical Mediastinoscopy in a Community Teaching Hospital
76. Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26
77. Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
78. Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
79. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
80. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies
81. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies
82. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
83. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
84. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
85. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)
86. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy
87. Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results
88. First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status
89. 1347P - Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
90. 1121P - Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26
91. 120P - Subgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC)
92. CEA: A Useful Prognostic Marker in Small Cell Lung Cancer
93. Nivolumab (Anti-Pd-1; Bms-936558, Ono-4538) in Combination with Platinum-Based Doublet Chemotherapy (Pt-Dc) or Erlotinib (Erl) in Advanced Non-Small Cell Lung Cancer (Nsclc)
94. Pooled Analysis of the Prognostic and Predictive Value of Kras Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer (Nsclc) Treated with Egfr Tkis (E-Tki)
95. Prognostic and Predictive Roles of Egfr Copy Number and Kras Mutation Status from the Radiant Trial of Adjuvant Erlotinib (E) Versus Placebo (P)
96. Egfr Del19/L858R Activating Mutation (M+) Subgroup in Radiant: Baseline Characteristics, Prognostic Role, and Disease-Free Survival (Dfs) By Stage
97. Common and Rare Egfr Mutations (Egfrm) in the Radiant Trial
98. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
99. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
100. An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.